Cargando…

The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070

Detalles Bibliográficos
Autores principales:	Fricker, Simon, Mosi, Renee, Anastassova, Virginia, Labrecque, Jean, Wong, Rebecca, Skerlj, Renato, Bridger, Gary, Huskens, Dana, Schols, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360399/ http://dx.doi.org/10.1186/1742-4690-9-S1-P7

Ejemplares similares

Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
por: O'Boyle, G, et al.
Publicado: (2013)

PRO 2000, a broadly active anti-HIV sulfonated compound, inhibits viral entry by multiple mechanisms
por: Huskens, Dana, et al.
Publicado: (2010)

Macrocyclic polyamines inhibit HIV infection by interacting with the cellular HIV co-receptors CXCR4 and CCR5
por: Schols, Dominique, et al.
Publicado: (2009)

AMD3100/CXCR4 Inhibitor
por: De Clercq, Erik
Publicado: (2015)

Algal Lectins as Potential HIV Microbicide Candidates
por: Huskens, Dana, et al.
Publicado: (2012)

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
por: Broxmeyer, Hal E., et al.
Publicado: (2005)

CXCR7/ACKR3-targeting ligands interfere with X7 HIV-1 and HIV-2 entry and replication in human host cells
por: D'huys, Thomas, et al.
Publicado: (2018)

Genotype–phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4(WHIM) variants
por: Zmajkovicova, Katarina, et al.
Publicado: (2022)

CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
por: Nishimura, Yukihide, et al.
Publicado: (2011)

D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II
por: Gori, Sadakatali S., et al.
Publicado: (2022)

Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore‐based virtual screening approach
por: Mirza, Muhammad Usman, et al.
Publicado: (2020)

CXCR4 Antagonist AMD3100 Modulates Claudin Expression and Intestinal Barrier Function in Experimental Colitis
por: Xia, Xian-Ming, et al.
Publicado: (2011)

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro
por: Kim, Ha-Yon, et al.
Publicado: (2010)

Targeting CXCL12/CXCR4 Signaling with AMD3100 Might Selectively Suppress CXCR4+ T-Cell Chemotaxis Leading to the Alleviation of Chronic Prostatitis
por: Zhang, Meng, et al.
Publicado: (2022)

Dengue Virus Entry as Target for Antiviral Therapy
por: Alen, Marijke M. F., et al.
Publicado: (2012)

Signaling properties of the human chemokine receptors CXCR4 and CXCR7 by cellular electric impedance measurements
por: Doijen, Jordi, et al.
Publicado: (2017)

CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation
por: Zhou, Jun, et al.
Publicado: (2020)

Inhibition of CXCR4 in Spinal Cord and DRG with AMD3100 Attenuates Colon-Bladder Cross-Organ Sensitization
por: Zhang, Hengshuai, et al.
Publicado: (2022)

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers
por: Liisborg, Charlotte, et al.
Publicado: (2022)

Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies
por: Soave, Mark, et al.
Publicado: (2020)

Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model
por: Kang, Yubin, et al.
Publicado: (2010)

MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias
por: Spinello, I, et al.
Publicado: (2011)

Synthesis and Evaluation of [(67)Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4
por: Aghanejad, Ayuob, et al.
Publicado: (2014)

CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats
por: Mason, Briana, et al.
Publicado: (2021)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo
por: Ling, Xiaoyang, et al.
Publicado: (2013)

V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100
por: Maeda, Yosuke, et al.
Publicado: (2014)

Establishment of a novel CCR5 and CXCR4 expressing CD4(+ )cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists
por: Princen, Katrien, et al.
Publicado: (2004)

CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2–DOP receptor heterodimer
por: Parenty, Geraldine, et al.
Publicado: (2008)

AMD AM29116
Publicado: (1982)

Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors
por: Van Hout, Anneleen, et al.
Publicado: (2017)

Epithelial chemokine CXCL14 synergizes with CXCL12 via allosteric modulation of CXCR4
por: Collins, Paul J., et al.
Publicado: (2017)

HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration, and invasion in lung cancer
por: Muralidharan, Ranganayaki, et al.
Publicado: (2015)

CXCR4 antagonist AMD3100 elicits analgesic effect and restores the GlyRα3 expression against neuropathic pain
por: Liu, Xiaoming, et al.
Publicado: (2017)

The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Wang, Shan, et al.
Publicado: (2020)

Comparison of the Response to the CXCR4 Antagonist AMD3100 during the Development of Retinal Organoids Derived from ES Cells and Zebrafish Retina
por: Wu, Yihui, et al.
Publicado: (2022)

Corrigendum to ‘Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach’ [European Journal of Pharmaceutical Sciences 155 (2020) 105537]
por: Mirza, Muhammad Usman, et al.
Publicado: (2021)

Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors
por: Di Martino, Simona, et al.
Publicado: (2020)

Finding Fusin/CXCR4, the First “2nd Receptor” for HIV Entry
por: Berger, Edward A.
Publicado: (2015)

Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
por: Schols, Dominique, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_cal3kafd8dirnd70jrg7likhls